MLK3 is required for mitogen activation of B-Raf, ERK and cell proliferation

Nature Cell Biology

Volumn 6, Issue 8, 2004, Pages 770-776

  Chadee, Deborah N ^a,b   Kyriakis, John M ^a,b  

^a TUFTS MEDICAL CENTER   (United States)

^b TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; MITOGEN ACTIVATED PROTEIN KINASE; MIXED LINEAGE KINASE 3; NEUROFIBROMIN; RAF PROTEIN; RAS PROTEIN; SERINE; STRESS ACTIVATED PROTEIN KINASE; SYNAPTOPHYSIN; THREONINE; UNCLASSIFIED DRUG; MITOGEN ACTIVATED PROTEIN KINASE KINASE KINASE; MITOGEN-ACTIVATED PROTEIN KINASE KINASE KINASE 11; MITOGENIC AGENT;

ANIMAL CELL; ARTICLE; CARCINOGENICITY; CELL PROLIFERATION; CELL STIMULATION; CONTROLLED STUDY; ENZYME ACTIVATION; ENZYME INHIBITION; GENE MUTATION; GENE SILENCING; HUMAN; HUMAN CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN FUNCTION; PROTEIN PHOSPHORYLATION; REGULATORY MECHANISM; RNA INTERFERENCE; TUMOR CELL LINE; CELL DIVISION; CELL LINE; CELL STRAIN HT29; CHEMISTRY; CYTOLOGY; DRUG EFFECT; ENZYMOLOGY; GENETICS; LEUKEMIA CELL LINE; METABOLISM; PHOSPHORYLATION; PHYSIOLOGY; UMBILICAL VEIN; VASCULAR ENDOTHELIUM;

ANIMALIA;

CELL DIVISION; CELL LINE; ENDOTHELIUM, VASCULAR; ENZYME ACTIVATION; GENE SILENCING; HT29 CELLS; HUMANS; JURKAT CELLS; MAP KINASE KINASE KINASES; MITOGEN-ACTIVATED PROTEIN KINASES; MITOGENS; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS C-RAF; RNA INTERFERENCE; SERINE; THREONINE; UMBILICAL VEINS;

EID: 4143098266     PISSN: 14657392     EISSN: None     Source Type: Journal    
DOI: 10.1038/ncb1152     Document Type: Article

References (30)

1. Kyriakis, J. M. in Protein Kinase Functions (ed. Woodgett, J. R.) 40-156 (Oxford University Press, Oxford, 2000).
2. Wojnowski, L. et al. Endothelial apoptosis in Braf-deficient mice. Nature Genet. 16, 293-297 (1997).
3. Wojnowski, L. et al. Overlapping and specific functions of Braf and Craf-1 proto-oncogenes during mouse embryogenesis. Mech. Dev. 91, 97-104 (2000).
4. Gallo, K. A. & Johnson, G. L. Mixed-lineage kinase control of JNK and p38 MAPK pathways. Nature Rev. Mol. Cell. Biol. 3, 663-672 (2002).
5. Sathyanarayana, P. et al. Activation of the Drosophila MLK by ceramide reveals TNF-α and ceramide as agonists of mammalian MLK3. Mol. Cell 10, 1527-1533 (2002).
6. Shen, Y. H. et al. Cross-talk between JNK/SAPK and ERK/MAPK pathways: sustained activation of JNK blocks ERK activation by mitogenic factors. J. Biol. Chem. 278, 26715-26721 (2003).
7. Zhang, B.-H. & Guan, K.-L. Activation of B-Raf kinase requires phosphorylation of the conserved residues Thr598 and Ser601. EMBO J. 19, 5429-5439 (2000).
8. Chong, H., Lee, J. & Guan, K.-L. Positive and negative regulation of Raf kinase activity and function by phosphorylation. EMBO J. 20, 3716-3727 (2001).
9. Davies, H. et al. Mutations of the BRAF gene in human cancer. Nature 417, 949-954 (2002).
10. Malumbres, M. & Barbacid, M. RAS oncogenes: the first 30 years. Nature Rev. Cancer 3, 459-465 (2003).
11. McCormick, F. Activators and effectors of ras p21 proteins. Curr. Opin. Genet. Dev. 4, 71-76 (1994).
12. Marshall, C. J. Ras effectors. Curr. Opin. Cell Biol. 8, 197-204 (1996).
13. Downward, J. Targeting RAS signalling pathways in cancer therapy. Nature Rev. Cancer. 3, 11-22 (2003).
14. Cichowski, K. & Jacks, T. NF1 tumor suppressor gene function: narrowing the GAP. Cell 104, 593-604 (2001).
15. Lynch, T. M. & Gutmann, D. H. Neurofibromatosis 1. 20, 841-865 (2002).
16. Elbashir, S. M. et al. Duplexes of 21-nucleotide RNAs mediate RNA interference in cultured mammalian cells. Nature 411, 494-498 (2001).
17. Chi, J. T. et al. Genomewide view of gene silencing by small interfering RNAs. Proc. Natl Acad. Sci. USA. 100, 6343-6346 (2003).
18. Semizarov, D. et al. Specificity of short interfering RNA determined through gene expression signatures. Proc. Natl Acad. Sci. USA. 100, 6347-6352 (2003).
19. Kyriakis, J. M. et al. The stress-activated protein kinase subfamily of c-Jun kinases. Nature 369, 156-160 (1994).
20. Dumitru, C. D. et al. TNF-α induction by LPS is regulated posttranscriptionally via a Tpl-2/ERK-dependent pathway. Cell 103, 1071-1083 (2000).
21. Sledz, C. A., Holko, M., de Veer, M. J., Silverman, R. H. & Williams, B. R. G. Activation of the interferon system by short-interfering RNAs Nature Cell Biol. 5, 834-839 (2003).
22. Wan, P. T C. et al. Mechanism of activation of the Raf-ERK signaling pathway by oncogenic mutation of B-RAF. Cell 116, 855-867 (2004).
23. Mercer, K. E. & Pritchard, C. A. Raf proteins and cancer: B-Raf is identified as a mutational target. Biochim. Biophys. Acta 1653, 25-40 (2003).
24. Mansour, S. J. et al. Transformation of mammalian cells by constitutively active MAP kinase kinase. Science 265, 966-970 (1994).
25. Lavoie, J. N., L'Allemain, G., Brunet, A., Müller, R. & Pouysségur, J. Cyclin D1 expression is regulated positively by the p42/p44 MAPK and negatively by the p38/HOG MAPK pathway. J. Biol. Chem. 271, 20608-20616 (1996).
26. Brunet, A. et al. Nuclear translocation of p42/p44 mitogen-activated protein kinase is required for growth factor-induced gene expression and cell cycle entry. EMBO J. 18, 664-674 (1999).
27. Balmanno, K. & Cook, S. J. Sustained MAP kinase activation is required for the expression of cyclin D1, p21 Cip1 and a subset of AP-1 proteins in CCL39 cells. Oncogene 18, 3085-3097 (1999).
28. Swenson, K. I., Winkler, K. E. & Means, A. R. A new identity for MLK3 as a NIMA-related, cell cycle-regulated kinase that is localized near centrosomes and influences microtubule organization. Mol. Biol. Cell 14, 156-172 (2003).
29. Sherr, C. J. The Pezcoller lecture: cancer cell cycles revisited. Cancer Res. 60, 3689-3695 (2000).
30. McClatchey, A. I. Merlin and ERM proteins: unappreciated roles in cancer development? Nature Rev. Cancer 3, 877-883 (2003).